Renal Impairment: In patients treated with GLP-1 receptor agonists, including Saxenda , there have been reports of acute renal failure and worsening of chronic renal failure, usually in association with nausea, vomiting, diarrhea, or dehydration, which may sometimes require hemodialysis
Management of Late-Onset Nodules The management of late-onset nodules depends on the underlying cause and the severity of the symptoms
Tirzepatide (MOUNJARO) Pronounced: tir ZEP a tide / mown JAHR OH Mnemonic: Tear zeppelin (over) Mount (Kiliman)jaro Year of release: 2022 Cost: $1060 / mo FDA-approved for: Type 2 diabetes Mechanism: dual GLP-1/GIP receptor agonist Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly subcutaneous injection) Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none significant in a bubble Tirzepatide (Mounjaro) is the first twincretin for type 2 diabetes
At TIXiMED, we are excited to share new peer-reviewed data on #TIX100, published in Diabetes, Obesity and Metabolism by investigators at the UAB Comprehensive Diabetes Center
